LG to Develop AI for Alzheimer's Treatment with US Genomic Research Institute

Joint Research and Development of AI to Uncover Disease Secrets

LG has decided to collaborate on artificial intelligence (AI) joint research and development with the Jackson Laboratory (JAX), a world-renowned nonprofit genome research institution in the United States, to unravel the secrets of Alzheimer's disease and cancer.

LG AI Research Institute and JAX announced on the 11th that following a partnership agreement signed in December last year, they recently finalized the main contract to promote this project.

From the left, Park Yong-min, Head of Healthcare Business at LG AI Research, Lee Hwa-young, Head of Business Development Unit, and Bae Kyung-hoon, Director, are taking a commemorative photo after signing a joint AI research and development agreement for Alzheimer's and cancer treatment with Jackson Lab's CEO Ron Cardon, CDO Paul Plicek, and Charles Lee, Director of the Genomic Medicine Institute. /

The two organizations will develop AI models that analyze the causes and progression of Alzheimer's and cancer and predict the effectiveness of treatments, laying the foundation for personalized treatment research. LG’s generative AI 'EXAONE' will be trained with JAX’s genetic characteristics of Alzheimer's and lifecycle research data to analyze disease causes and enhance treatment efficiency.

JAX is a genome-specialized research institution that designs and produces genetically modified mice. It possesses a vast amount of research data related to various genetic variations and mutant genes associated with diseases such as Alzheimer's and cancer. LG Electronics explains that combining this with LG’s AI technology is expected to create significant synergy.

LG AI Research Institute and JAX will also jointly develop AI models active in cancer diagnosis and treatment. They plan to develop a multimodal generative AI model that rapidly diagnoses cancer and predicts treatment effectiveness using only pathology images, as well as a new conversational generative AI model that proposes personalized anticancer treatment options to doctors based on individual genomic information characteristics.

Both parties expect AI to contribute to shortening the development time and increasing the success rate from new drug candidate discovery to preclinical and clinical trials in the cancer field. They also foresee that the AI models developed through their collaboration will play a role in ushering in an era of precision medicine that enables personalized treatment according to genetic mutations.

Baek Gwang-hoon, head of LG AI Research Institute, said, "LG AI Research Institute has been continuously conducting research and development to apply AI to various industrial fields," adding, "Especially in the bio sector, which is LG’s future growth engine, we will actively continue research and development to achieve meaningful results through AI technology."

LG is strengthening its capabilities to nurture A·B·C (AI·Bio·Cleantech) as future growth engines. In particular, it is focusing on accelerating innovation in the bio sector, such as new drug development using AI.

Gu Kwang-mo, CEO of LG Corporation, visited Boston, USA, and Toronto, Canada, in August last year to review the status of future preparations and nurturing strategies in the bio and AI fields. Regarding the future potential of the bio business, he emphasized, "Although it is a small seed now, if we continue to strive and challenge without faltering, it will grow into a future giant representing LG."

In 2022, LG AI Research Institute developed a 'neoantigen prediction AI model' that induces the death of cancer cells using patients’ genetic information and cancer cell mutation data. In July last year, it publicly launched the generative AI platform for developing new drugs, new materials, and new substances, 'EXAONE Discovery.'

This content was produced with the assistance of AI translation services.